MDM2 and neuroblastoma: Considering that nearly all neuroblastomas have an intact and wild-type;p53 in conjunction with the improved potency and bioavailability of this latest generation MDM2 inhibitor, RG7388 is a promising, non-genotoxic, targeted therapy for the treatment of neuroblastoma and other p53 wild-type solid tumors.